When you contact us about a possible GLP-1 vision loss case, we will: Review your medication history, including GLP-1 prescriptions and any compounded or telehealth-supplied products Obtain and analyze your ophthalmology, neuro-ophthalmology, and hospital records Build a detailed timeline of your symptoms and treatment Consult with medical experts to evaluate whether your vision loss is consistent with NAION or another drug-related optic neuropathy Advise you on whether your case may be pursued within the existing MDL framework, as an individual lawsuit, or in state court Advocate for full compensation for the impact this injury has had on your life and your family You do not have to navigate the medical and legal uncertainty around GLP-1 drugs and vision loss alone
We currently have a randomised, placebo-controlled human clinical study in progress for the product
[Article] [PubMed]63
Cardiovascular risk reduction For type 2 diabetes patients with established cardiovascular disease, GLP-1 receptor agonists are preferred over insulin due to their proven cardiovascular benefits
Contrave is an oral prescription medication combining two active ingredients: naltrexone and bupropion
Patients with obesity are more likely to discontinue GLP-1 therapy than those with diabetes, citing lower perceived necessity, stigma, and limited coverage as key drivers 7
